Background A phase 2 trial of tocilizumab showed preliminary evidence of efficacy in
systemic sclerosis. We assessed skin fibrosis and systemic sclerosis-associated interstitial …

Background Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid
arthritis. The Oral Rheumatoid Arthritis triaL (ORAL) Strategy aimed to assess the …

Background Odanacatib, a cathepsin K inhibitor, reduces bone resorption while maintaining
bone formation. Previous work has shown that odanacatib increases bone mineral density in …

Many rheumatic diseases may present with an inflammatory joint syndrome, affecting the
small joints of the hands, of which rheumatoid (RA) and psoriatic arthritis (PsA) being one of …

Objective Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA).
The phase III, 24‐month, placebo‐controlled Oral Rheumatoid Arthritis (ORAL) Scan trial …

Objective To investigate the pharmacodynamics, pharmacokinetics and safety of cenerimod—
a potent, oral, selective sphingosine 1-phosphate 1 receptor modulator—in patients with …

Systemic sclerosis (SSc) is a rare autoimmune connective tissue disease characterized by
fibrosis of the skin and internal organs, autoimmunity-driven damage and vasculopathy. The …

YKL-40, also known as human cartilage glycoprotein 39, is a member of the “mammalian
chitinase-like proteins” family without chitinase activity. Increased serum concentrations are …

Patients with low back pain (LBP) frequently undergo various imaging studies in the pursuit
of a more precise diagnosis. Ultrasound (US) has the advantage of being a widely available …

Systemic sclerosis (SSc) is an autoimmune disease with completely undefined etiology and
treatment difficulties. The expression of both protein coding and non-coding RNAs is …